RxDoctor Payments DataLook up a doctor →

Steve-Felix Belinga, MD

Neurology · Fort Smith, ARNPI 1588817522

Payments from drug & device makers

$809,393in general payments, 2019–2025

Across 1,392 payments — averaging $581.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$523K
  • AbbVie$125K
  • Otsuka Pharmaceutical Development & Commercialization, Inc.$82K
  • Biohaven Pharmaceutical Holding Company Ltd.$27K
  • Biohaven Pharmaceuticals, Inc.$23K
  • Pfizer$9K
  • plus $22K from 53 others
$1,500in research payments, 2019–2025

Across 3 payments — averaging $500.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Pfizer$2K

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novartis123$522,632
AbbVie(2 entities)255$124,910
Otsuka Pharmaceutical Development & Commercialization, Inc.4$81,513
Biohaven Pharmaceutical Holding Company Ltd.38$27,238
Biohaven Pharmaceuticals, Inc.52$22,602
Pfizer61$8,700
Livanova USA, Inc.10$2,060
Abbott14$1,898
Supernus Pharmaceuticals, Inc.48$1,802
EMD Serono, Inc.90$1,744
SK Life Science, Inc.65$1,675
Amgen47$1,049
Neurocrine Biosciences, Inc.43$953
UCB, Inc.35$832
Teva Pharmaceuticals USA, Inc.46$721
MDD US Operations, LLC22$713
Kyowa Kirin, Inc.19$615
Eisai Inc.40$604
Biogen25$567
Sunovion Pharmaceuticals Inc.42$539
Bristol Myers Squibb28$518
Upsher-smith Laboratories LLC29$454
Lundbeck LLC18$448
Sanofi27$444
Genentech USA, Inc.21$417
Amneal Pharmaceuticals LLC19$389
Lilly USA, LLC23$314
AstraZeneca(2 entities)16$290
Johnson & Johnson(2 entities)18$288
Neurelis, Inc.11$245
Adamas Pharmaceuticals, Inc.12$214
Corium, LLC4$195
Sumitomo Pharma America, Inc.9$193
TG Therapeutics, Inc.6$156
Argenx US, Inc.7$151
Travere Therapeutics, Inc.1$125
ANI Pharmaceuticals, Inc.5$125
Axsome Therapeutics, Inc.4$107
Avanir Pharmaceuticals, Inc.6$94
Acorda Therapeutics, Inc5$90
E.r. Squibb & Sons, L.L.C.6$90
Catalyst Pharmaceuticals, Inc.5$84
Zyla Life Sciences, Inc.5$63
Averitas Pharma Inc.1$62
Merz Pharmaceuticals, LLC2$61
Acadia Pharmaceuticals Inc4$56
Jazz Pharmaceuticals Inc.2$55
Otsuka America Pharmaceutical, Inc.3$53
Sanofi-aventis U.S. LLC3$44
Harmony Biosciences LLC2$40
Banner Life Sciences, LLC2$30
Regeneron Healthcare Solutions, Inc.2$24
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)1$20
Aprecia Pharmaceuticals, LLC1$18
Strongbridge US Inc.1$15
Philips North America LLC1$15
Medtronic1$14
Promius Pharma LLC1$13
Impel Pharmaceuticals Inc.1$12

How this compares

$809,393 in reported general payments places this provider in the 95th percentile of 93 neurology providers in Arkansas.

See all neurology providers in Arkansas

Medicare billing

Part B allowed, 2024
$388,000
Medicare patients
715
Services billed
3,295

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other neurology in Fort Smith

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →